Research Tracker›Biomarker Atlas›Lyme Disease›B. burgdorferi EIA (screening)

B. burgdorferi EIA (screening) in Lyme Disease

B. burgdorferi EIA (screening), also described as Enzyme immunoassay — tier 1, belongs to the serologic group of Lyme Disease (Lyme borreliosis, Borrelia burgdorferi infection) markers and is reported to be raised relative to Uninfected. Clinically, it has been associated with active or past Lyme infection. The finding is drawn from Mead et al. 2019; it describes group-level differences, not a threshold that classifies an individual.

↑ ElevatedSerologic

Summary

Direction in Lyme Disease↑ Elevated — higher than in the comparison group
CategorySerologic
Also described asEnzyme immunoassay — tier 1
Compared againstUninfected
Associated symptomsActive or past Lyme infection
Test typeBlood test (serum / plasma / whole blood)
SourceMead et al. 2019 — doi:10.15585/mmwr.mm6832a4
Condition atlasLyme Disease Biomarker Atlas

Trials, interventions and tests

In clinical-trial registrations this marker maps to the outcome term Change in the ALC from Screening, INT1, FU1.3, INT2, FU2.3, FU2.4, FU2.5, and EOS. (25 registered trials use a matching outcome measure).

Clinical trials using B. burgdorferi EIA (screening) as an outcome

NCT07388550Not Yet Recruiting
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Outcome measure: The primary outcome of this study is to determine the safety of a single dose of intravenous Pembrolizumab in participants with neurological post-acute sequalae of SARS-CoV-2 infection.
NCT06404073Completed
RECOVER-ENERGIZE Platform Protocol_Appendix B (Structured Pacing (PEM))
Outcome measure: Change in orthostatic hypotension, as measured by the Modified Orthostatic Hypotension Questionnaire (mOHQ)
NCT07123727Recruiting
A Study to Examine Anktiva for the Treatment of COVID-19.
Outcome measure: Percent increase or decrease change in the Absolute lymphocyte count (as measured on CBC) from Screening to End Of Study with various timepoints.
NCT07798570Not Yet Recruiting
Observational Study With CICR-NAM as a Food for Special Medicinal Purposes in Post-COVID Syndrome (PCS)
Outcome measure: Serum tryptophan level
NCT07724834Not Yet Recruiting
CD19-B Cell Depletion in PAIS-ME/CFS Patients
Outcome measure: Improvement in cognitive function measured by the Symbol Digit Modalities Test (SDMT)
NCT06974084Not Yet Recruiting
A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID
Outcome measure: Fatigue
NCT07627815Recruiting
Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVID
Outcome measure: Change in distance walked on the 6-minute walk test (6MWT) after 6 weeks of treatment.
NCT07108036Recruiting
A Study to Assess Anktiva in Patients With Long Covid-19.
Outcome measure: Change in the ALC from Screening, INT1, FU1.3, INT2, FU2.3, FU2.4, FU2.5, and EOS.

17 more trials reference this marker.

Commercial test availability

Lyme Disease Antibody Screen (EIA) — commercial laboratory test.

Links are for reference only; availability, specimen requirements and coverage vary by location.

Related Serologic markers in Lyme Disease

Full list: Lyme Disease Biomarker Atlas.

Frequently asked questions

Is B. burgdorferi EIA (screening) high or low in Lyme Disease?

Elevated. Studies summarised in the OSMF atlas report higher B. burgdorferi EIA (screening) in Lyme Disease than in Uninfected. Source: Mead et al. 2019.

What symptoms is B. burgdorferi EIA (screening) associated with in Lyme Disease?

The cited literature associates this marker with Active or past Lyme infection. These are population-level associations and do not mean the marker causes the symptoms.

Which test measures B. burgdorferi EIA (screening)?

It is measured as a blood test (serum / plasma / whole blood). Commercial laboratories such as LabCorp, Quest Diagnostics list an orderable assay.

Is one abnormal B. burgdorferi EIA (screening) result diagnostic of Lyme Disease?

No. No single biomarker is diagnostic of Lyme Disease. B. burgdorferi EIA (screening) findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.

Cite this page

Open Source Medicine Foundation. (2026). B. burgdorferi EIA (screening) in Lyme Disease: direction, evidence and what it means. OSMF Research Tracker. Retrieved November 21, 2026, from https://research.opensourcemed.info/biomarkers/lyme/b-burgdorferi-eia-screening.html

Last reviewed: 2026-06-29 · Page generated from lyme.json · Browse: Lyme Disease atlas · Biomarker Index · All marker pages

Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.